1. Aims & Scope:
In the past few decades, malignancy (i.e. cancer) has been one of the most serious diseases around the world, which exhibits high morbidity and mortality. In spite of the considerable developments of various antitumor drugs, such as doxorubicin, paclitaxel, and chlorambucil, clinical outcomes have been disappointing due to the life-threatening side effects including leukemia and cardiotoxicity, etc. To eliminate or reduce the severe side effects, many kinds of polymeric nanocarriers, such as micelles, vesicles, liposomes and nanogels, have been developed as vehicles for the deliveries of antitumor drugs (i.e. polymeric nanomedicines). In general, the polymeric nanomedicines are well-engineered as nanoscale formulations for enhanced permeability and retention effect, biocompatible shells for long-circulation, multifunctional surfaces for targetability, and stimuli-responsiveness for "on-demand" drug delivery. Various merits such as enhanced drug loading, controlled release as well as improved therapeutic efficacy toward animal models have been achieved through the dexterous designs and accurate preparations of smart polymeric nanocarriers. In view of above discussion, the polymeric nanomedicines exhibit great potential for clinical malignancy therapy. In the current special issue, the past developments of polymeric nanomedicines for malignancy therapy will be reviewed, and the future advances will be predicted.

2. Key words:
Basic research, Biodegradable (co)polymer, Clinical application, Controlled release, Malignancy therapy, Nanomedicine, Self-assembly, Targetability

3. Subtopics:
1) The Opportunities and Challenges of Polymeric Nanomedicines for Malignancy Therapy
2) Nucleic Acid Drugs Translated by Polymeric Nanocarriers for Malignancy Therapy
3) Smart Polymeric Nanocarriers Originated from Cyclodextrins
4) Stimuli-Responsive Polymeric Nanocarriers for Antitumor Drug Delivery
5) Nanoscale Antitumor Polymeric Formulations with Great Prospects
Few more may be included in future.

4. Approximate Schedule:
- Manuscript Submission Deadline: 01/01/2015
- Peer Review Due: 02/02/2015
- Revision Due: 18/03/2015
- Notification of Acceptance by the Guest Editor: 21/07/2015
- Final Manuscript Due: 28/07/2015

5. A List of Names & Affiliations of Contributing Authors:
1) **Author(s):** Jianxun Ding, Chunsheng Xiao, Xiuli Zhuang and Xuesi Chen  
**Affiliation(s):** Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, P. R. China  
**Email:** jxding@ciac.ac.cn  
**Tentative Title:** The Opportunities and Challenges of Polymeric Nanomedicines for Malignancy Therapy

2) **Author(s):** Quanshun Li, Wei Shi, et al.  
**Affiliation(s):** Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, College of Life Science, Jilin University, P. R. China  
**Email:** qsli06@mails.jlu.edu.cn  
**Tentative Title:** Nucleic Acid Drugs Translated by Polymeric Nanocarriers for Malignancy Therapy

3) **Author(s):** Ruxandra Gref, et al.  
**Affiliation(s):** Faculté de Pharmacie (CNRS 8612), Université Paris-Sud, France  
**Email:** ruxandra.gref@u-psud.fr  
**Tentative Title:** Smart Polymeric Nanocarriers Originated from Cyclodextrins

4) **Author(s):** Thanh Thi Kim Nguyen, et al.  
**Affiliation(s):** Department of Physics and Astronomy, University College London, United Kingdom  
**Email:** ntk.thanh@ucl.ac.uk  
**Tentative Title:** Stimuli-Responsive Polymeric Nanocarriers for Antitumor Drug Delivery

5) **Author(s):** Zhonggui He, et al.  
**Affiliation(s):** Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, P. R. China  
**Email:** hezhonggui@gmail.com  
**Tentative Title:** Nanoscale Antitumor Polymeric Formulations with Great Prospects